Suven Life Sciences, a biopharmaceutical company focused on discovery, developing and commercializing novel pharmaceutical products, has received two product patents from Japanese Patent Office (JPO) for its New Chemical Entities (NCE's) in respect of the treatment of disorders associated with neurodegenerative diseases. These patents are valid until 2022. With these approvals, Suven's list of patent approvals reach at three products in Japan.
The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents. According to the invention 4460446 patent disclosure, the compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.
Several product patent applications are in the pipeline and Suven secured intellectual property protection for several of their NCEs in all major markets like USA, Canada, Europe, China, Russia, India, Japan, Australia, New Zealand, Brazil and Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal drug discovery research efforts. Products out of these inventions may be out-licensed at the stage of clinical phase-1 or phase-II.
Venkat Jasti, CEO, said, “We are very pleased by the grant of these patents to Suven by Japanese patent office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has a estimated $20 billion market potential globally.” The company has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions.